|Mr. Vijay B. Samant||CEO, Pres & Director||905.94k||N/A||1953|
|Mr. Anthony Alan Ramos||VP, CFO & Chief Accounting Officer||336.63k||N/A||1967|
|Dr. Lawrence Russell Smith||Sr. VP of Research||360.95k||N/A||1961|
|Dr. Mammen P. Mammen Jr.||Sr. VP of Clinical Devel.||N/A||N/A||1964|
|Mr. Keith D. Hall||VP of Operations||N/A||N/A||1962|
Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company is developing VCL-HB01, an HSV-2 therapeutic vaccine that is in Phase II clinical trial to prevent and protect against lesion recurrence, as well as for the treatment of patients with symptomatic genital herpes infection; VL-2397 antifungal program, which is in Phase II clinical trial for the treatment of invasive fungal infections; and chronic hepatitis B that is in preclinical stage for the eradication of persistent HBV infection. Vical Incorporated has a license agreement with Astellas Pharma Inc. to develop and commercialize VL-2397 antifungal candidate. The company was founded in 1987 and is headquartered in San Diego, California.
Vical Incorporated’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.